Department of Gynecology and Obstetrics, Development and Related Disease of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, China.
Front Immunol. 2022 Sep 15;13:915094. doi: 10.3389/fimmu.2022.915094. eCollection 2022.
Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for various cancer types. Multiple single or combinations of ICB treatments have been approved by the US Food and Drug Administration, providing more options for patients with advanced cancer. However, most patients could not benefit from these immunotherapies due to primary and acquired drug resistance. Thus, a better understanding of the mechanisms of ICB resistance is urgently needed to improve clinical outcomes. Here, we focused on the changes in the biological functions of CD8 T cells to elucidate the underlying resistance mechanisms of ICB therapies and summarized the advanced coping strategies to increase ICB efficacy. Combinational ICB approaches and individualized immunotherapies require further in-depth investigation to facilitate longer-lasting efficacy and a more excellent safety of ICB in a broader range of patients.
免疫检查点阻断（ICB）迅速改变了多种癌症类型的治疗模式。美国食品和药物管理局已经批准了多种单药或联合 ICB 治疗方法，为晚期癌症患者提供了更多选择。然而，由于原发性和获得性药物耐药性，大多数患者无法从这些免疫疗法中获益。因此，迫切需要更好地了解 ICB 耐药性的机制，以改善临床结果。在这里，我们专注于 CD8 T 细胞生物学功能的变化，以阐明 ICB 治疗的潜在耐药机制，并总结了提高 ICB 疗效的先进应对策略。联合 ICB 方法和个体化免疫疗法需要进一步深入研究，以促进更广泛的患者群体中 ICB 更长时间的疗效和更优异的安全性。
